Beyond Risk Management: RMPs Provide Opportunity for Post-Marketing Drug Development and Product Differentiation

The Ministry of Health, Labor and Welfare (MHLW) introduced on April 1 a new system that will require drug makers to submit pharmaceutical risk management plans (RMPs) when they file applications for the approval of new drugs and biosimilars. Since...read more